Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 26, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Atoptic Dermatitis
Interventions
DRUG

EVO756

Dose 1

DRUG

EVO756

Dose 2

DRUG

EVO756

Dose 3

DRUG

Placebo control

Placebo control

Trial Locations (12)

10023

RECRUITING

Equity Medical, New York

13057

RECRUITING

Empire Dermatology, East Syracuse

14623

RECRUITING

Skin Search of Rochester, Inc., Rochester

33021

RECRUITING

Skin Care Research - Hollywood Dermatology, Hollywood

33134

RECRUITING

Driven Research, LLC, Coral Gables

33486

RECRUITING

Skin Care Research, LLC, Boca Raton

37130

RECRUITING

International Clinical Research - Murfreesboro, Murfreesboro

78213

RECRUITING

Progressive Clinical Research, San Antonio

84095

RECRUITING

Jordan Valley Dermatology Center, South Jordan

90017

RECRUITING

Metropolis Dermatology - Downtown Los Angeles, Los Angeles

91105

RECRUITING

Skin and Beauty Center, Pasadena

94538

RECRUITING

Center for Dermatology Clinical Research, Fremont

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Evommune, Inc.

INDUSTRY

NCT07150845 - Phase 2b Study of EVO756 in Adults With Atopic Dermatitis | Biotech Hunter | Biotech Hunter